Prognostic value of the inverse platelet to lymphocyte ratio (iPLR) in patients with multiple myeloma who were treated up front with a novel agent-containing regimen

Sung Hoon Jung, Jin Seok Kim, Won Sik Lee, Suk Joong Oh, Jae Sook Ahn, Deok Hwan Yang, Yeo Kyeoung Kim, Hyeoung Joon Kim, Je Jung Lee

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Recently, reactive thrombosis or platelet to lymphocyte ratio has been reported as a strong predictor of poor prognosis in various types of cancer. However, a study investigating the relationship between platelet counts and thrombopoietic cytokines suggested that low platelet could be important in multiple myeloma (MM), which means platelet count decreased in advanced International Staging System (ISS) stage. Therefore, we developed inverse platelet to lymphocyte ratio (iPLR) and assessed the prognostic value of iPLR in patients with MM. We retrospectively analyzed 283 patients who were treated up front with a novel agent-containing regimen. Patients were classified into three groups based on hazard ratio (HR) according to iPLR: low iPLR (group 1), middle iPLR (group 2), and high iPLR (group 3). Over a median follow-up of 34.8 months, staging by iPLR group had predictive value for progression-free survival (PFS) and overall survival (OS). In addition, staging by iPLR group was a reliable method to predict for survival in patients who presented with renal failure (eGFR < 60 mL/min/1.73 m2) and in elderly patients. Multivariate analyses demonstrated that staging by iPLR group was associated with PFS and OS in patients with MM. In conclusion, this study suggested that iPLR is a simple and reliable inflammatory prognostic factor in the era of novel agents.

Original languageEnglish
Pages (from-to)55-61
Number of pages7
JournalAnnals of Hematology
Volume95
Issue number1
DOIs
Publication statusPublished - 2016 Jan 1

Fingerprint

Multiple Myeloma
Blood Platelets
Lymphocytes
Platelet Count
Disease-Free Survival
Survival
Renal Insufficiency
Thrombosis
Multivariate Analysis
Cytokines

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Jung, Sung Hoon ; Kim, Jin Seok ; Lee, Won Sik ; Oh, Suk Joong ; Ahn, Jae Sook ; Yang, Deok Hwan ; Kim, Yeo Kyeoung ; Kim, Hyeoung Joon ; Lee, Je Jung. / Prognostic value of the inverse platelet to lymphocyte ratio (iPLR) in patients with multiple myeloma who were treated up front with a novel agent-containing regimen. In: Annals of Hematology. 2016 ; Vol. 95, No. 1. pp. 55-61.
@article{92e3ce258e01413f8e9ebe91d4059690,
title = "Prognostic value of the inverse platelet to lymphocyte ratio (iPLR) in patients with multiple myeloma who were treated up front with a novel agent-containing regimen",
abstract = "Recently, reactive thrombosis or platelet to lymphocyte ratio has been reported as a strong predictor of poor prognosis in various types of cancer. However, a study investigating the relationship between platelet counts and thrombopoietic cytokines suggested that low platelet could be important in multiple myeloma (MM), which means platelet count decreased in advanced International Staging System (ISS) stage. Therefore, we developed inverse platelet to lymphocyte ratio (iPLR) and assessed the prognostic value of iPLR in patients with MM. We retrospectively analyzed 283 patients who were treated up front with a novel agent-containing regimen. Patients were classified into three groups based on hazard ratio (HR) according to iPLR: low iPLR (group 1), middle iPLR (group 2), and high iPLR (group 3). Over a median follow-up of 34.8 months, staging by iPLR group had predictive value for progression-free survival (PFS) and overall survival (OS). In addition, staging by iPLR group was a reliable method to predict for survival in patients who presented with renal failure (eGFR < 60 mL/min/1.73 m2) and in elderly patients. Multivariate analyses demonstrated that staging by iPLR group was associated with PFS and OS in patients with MM. In conclusion, this study suggested that iPLR is a simple and reliable inflammatory prognostic factor in the era of novel agents.",
author = "Jung, {Sung Hoon} and Kim, {Jin Seok} and Lee, {Won Sik} and Oh, {Suk Joong} and Ahn, {Jae Sook} and Yang, {Deok Hwan} and Kim, {Yeo Kyeoung} and Kim, {Hyeoung Joon} and Lee, {Je Jung}",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/s00277-015-2521-x",
language = "English",
volume = "95",
pages = "55--61",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "1",

}

Prognostic value of the inverse platelet to lymphocyte ratio (iPLR) in patients with multiple myeloma who were treated up front with a novel agent-containing regimen. / Jung, Sung Hoon; Kim, Jin Seok; Lee, Won Sik; Oh, Suk Joong; Ahn, Jae Sook; Yang, Deok Hwan; Kim, Yeo Kyeoung; Kim, Hyeoung Joon; Lee, Je Jung.

In: Annals of Hematology, Vol. 95, No. 1, 01.01.2016, p. 55-61.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prognostic value of the inverse platelet to lymphocyte ratio (iPLR) in patients with multiple myeloma who were treated up front with a novel agent-containing regimen

AU - Jung, Sung Hoon

AU - Kim, Jin Seok

AU - Lee, Won Sik

AU - Oh, Suk Joong

AU - Ahn, Jae Sook

AU - Yang, Deok Hwan

AU - Kim, Yeo Kyeoung

AU - Kim, Hyeoung Joon

AU - Lee, Je Jung

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Recently, reactive thrombosis or platelet to lymphocyte ratio has been reported as a strong predictor of poor prognosis in various types of cancer. However, a study investigating the relationship between platelet counts and thrombopoietic cytokines suggested that low platelet could be important in multiple myeloma (MM), which means platelet count decreased in advanced International Staging System (ISS) stage. Therefore, we developed inverse platelet to lymphocyte ratio (iPLR) and assessed the prognostic value of iPLR in patients with MM. We retrospectively analyzed 283 patients who were treated up front with a novel agent-containing regimen. Patients were classified into three groups based on hazard ratio (HR) according to iPLR: low iPLR (group 1), middle iPLR (group 2), and high iPLR (group 3). Over a median follow-up of 34.8 months, staging by iPLR group had predictive value for progression-free survival (PFS) and overall survival (OS). In addition, staging by iPLR group was a reliable method to predict for survival in patients who presented with renal failure (eGFR < 60 mL/min/1.73 m2) and in elderly patients. Multivariate analyses demonstrated that staging by iPLR group was associated with PFS and OS in patients with MM. In conclusion, this study suggested that iPLR is a simple and reliable inflammatory prognostic factor in the era of novel agents.

AB - Recently, reactive thrombosis or platelet to lymphocyte ratio has been reported as a strong predictor of poor prognosis in various types of cancer. However, a study investigating the relationship between platelet counts and thrombopoietic cytokines suggested that low platelet could be important in multiple myeloma (MM), which means platelet count decreased in advanced International Staging System (ISS) stage. Therefore, we developed inverse platelet to lymphocyte ratio (iPLR) and assessed the prognostic value of iPLR in patients with MM. We retrospectively analyzed 283 patients who were treated up front with a novel agent-containing regimen. Patients were classified into three groups based on hazard ratio (HR) according to iPLR: low iPLR (group 1), middle iPLR (group 2), and high iPLR (group 3). Over a median follow-up of 34.8 months, staging by iPLR group had predictive value for progression-free survival (PFS) and overall survival (OS). In addition, staging by iPLR group was a reliable method to predict for survival in patients who presented with renal failure (eGFR < 60 mL/min/1.73 m2) and in elderly patients. Multivariate analyses demonstrated that staging by iPLR group was associated with PFS and OS in patients with MM. In conclusion, this study suggested that iPLR is a simple and reliable inflammatory prognostic factor in the era of novel agents.

UR - http://www.scopus.com/inward/record.url?scp=84952982217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952982217&partnerID=8YFLogxK

U2 - 10.1007/s00277-015-2521-x

DO - 10.1007/s00277-015-2521-x

M3 - Article

C2 - 26467916

AN - SCOPUS:84952982217

VL - 95

SP - 55

EP - 61

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 1

ER -